348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
In: Annals of Oncology, Jg. 31 (2020-09-01), S. S386- (2S.)
Online
unknown
Zugriff:
Titel: |
348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
|
---|---|
Autor/in / Beteiligte Person: | Aftimos, P.G. ; Larsimont, D. ; Canon, J-L ; Paesmans, Marianne ; Eiger, Daniel ; Poncin, R. ; Piccart, M.J. ; Velghe, C. ; Taylor, D. ; Craciun, Ligia ; Punie, Kevin ; Casert, V. ; Brandao, M. ; Clatot, Florian ; Buisseret, Laurence ; E. de Azambuja ; Duhoux, François ; Ignatiadis, M ; T. Van den Mooter ; Maurer, Christian |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 31 (2020-09-01), S. S386- (2S.) |
Veröffentlichung: | Elsevier BV, 2020 |
Medientyp: | unknown |
ISSN: | 0923-7534 (print) |
DOI: | 10.1016/j.annonc.2020.08.450 |
Schlagwort: |
|
Sonstiges: |
|